NEXTCURE, INC Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
NEXTCURE, INC (NXTC) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost of $4.83 million as of 2026-06-30, per its S-4 filed 2026-08-18.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis · last filed 2026-08-18
- 2026-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $4.83M.
- 2026-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $14.58M.
- 2025-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $15.82M.
- 2025-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $21.77M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost |
|---|---|
| 2026-06-30 | $4.83M S-4 · filed 2026-08-18 |
| 2026-03-31 | $14.58M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $15.82M S-4 · filed 2026-08-18 |
| 2025-09-30 | $21.77M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $30.42M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $34.03M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $40.89M 10-K · filed 2025-03-06 |
| 2024-09-30 | $47.53M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $65.67M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $77.83M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $95.44M 10-K · filed 2024-03-21 |
| 2023-09-30 | $99.29M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $109.53M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $116.32M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $134.78M 10-K · filed 2023-03-02 |
| 2022-09-30 | $140.56M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $159.67M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $192.87M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $207.92M 10-K · filed 2022-03-03 |
| 2021-09-30 | $198.80M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $214.81M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $231.53M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $249.90M 10-K · filed 2021-03-04 |
| 2019-12-31 | $300.55M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |